Testing for donor specific antibodies and baff for donor specific antibodies, immunoglobulin free light chains, and risk of late-onset ptld in liver recipients, in support of the NCI/dceg/IIB
Ended Purchase Order Awarded
- Contract number
- HHSN261201600033A
- Awardee
-
Terasaki Institute For Biomedical Innovation UEI Q3SPRLFLMS73
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $43,200
Award facts
- Opportunity
-
- N02CO626738 Solicitation number
- Testing for Donor Specific Antibodies and BAFF, for a study titled Donor Specific Antibodies, Immunoglobulin Free Light Chains, and Risk of Late-Onset PTLD in Liver Recipients Award Notice · Posted Aug 22, 2016
- Contract value 100% obligated
- $43,200.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Los Angeles, CA 90064, USA
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract HHSN261201600033A?
HHSN261201600033A was awarded to Terasaki Institute For Biomedical Innovation by National Cancer Institute (National Institutes of Health) on September 21, 2016.
How much is contract HHSN261201600033A worth?
The government has obligated $43,200 on HHSN261201600033A.
Was contract HHSN261201600033A competed?
The extent of competition for HHSN261201600033A was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award